Diabetes goes beyond just glucose control, and recent advancements in research are enhancing drug development for the disease.

Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest ...

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is ...

Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for ...

Colorectal cancer (CRC), particularly the immunologically “cold” microsatellite-stable (MSS) subtype, remains profoundly resistant to immune checkpoint inhibitors. Antibody-drug conjugates (ADCs) are ...

From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates dominated Europe’s leading cancer conference over the ...

Doing more with less in electronics often means improving power density. One of the new areas garnering attention involves applying a variety of advanced modulation techniques, including PWM and space ...

Many noise sources can plague high-speed radio-frequency (RF) analog signal chains, making design considerations that much more challenging. Both megahertz and sub-terahertz sampling-rate converters ...

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

Agree Realty Corporation offers a solid monthly yield of nearly 3%, a recession-resistant portfolio, and astute management, making it a strong buy despite seeming expensive. Q1 2025 earnings showed ...

Agree Realty offers a solid monthly yield near 3%, a recession-resistant portfolio, and astute management, making it a strong buy despite seeming expensive. The REIT's Q1 performance showed growth in ...